No Data
No Data
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
Neoleukin Therapeutics GAAP EPS of -$1.19 In-line
Neurogene: Q3 Earnings Snapshot
Neurogene | 10-Q: Quarterly report
Neurogene Reports Q3 EPS ($1.19), Consensus ($1.22)
Express News | Neurogene Inc: Strong Cash Position Provides Runway Into Second Half of 2027
No Data
No Data